Novel anti-melanoma treatment: Focus on immunotherapy

Chinese Journal of Cancer

Volumn 33, Issue 9, 2014, Pages 458-465

  Hao, Meng Ze ^a   Zhou, Wen Ya ^a   Du, Xiao Ling ^a   Chen, Ke Xin ^a   Wang, Guo Wen ^a   Yang, Yun ^a   Yang, Ji Long ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

CTLA 4; Cytokine; Immunotherapy; Melanoma; PD 1; Tumor vaccine

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DACARBAZINE; DENDRITIC CELL VACCINE; GANGLIOSIDE; INTERLEUKIN 2; IPILIMUMAB; MELANOMA ASSOCIATED ANTIGEN A3 VACCINE; NIVOLUMAB; OBLIMERSEN; PACLITAXEL; PEGINTERFERON ALPHA2B; PEMBROLIZUMAB; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; SELECTIKINE; TALIMOGENE LAHERPAREPVEC; TEMOZOLOMIDE; TICILIMUMAB; TRAMETINIB; TUMOR VACCINE; UNCLASSIFIED DRUG; URELUMAB; VEMURAFENIB;

BONE MARROW SUPPRESSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; FATIGUE; GENE MUTATION; HUMAN; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; INCIDENCE; INFECTION; LEUKOPENIA; LIVER TOXICITY; MELANOMA; METASTATIC MELANOMA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; UNSPECIFIED SIDE EFFECT;

HUMANS; IMMUNOTHERAPY; MELANOMA;

EID: 84907502495     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.014.10118     Document Type: Review

References (85)

1. Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist, 2011,16:5-24.
2. Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer, 2011,47:2150-2157.
3. Jang S, Atkins MB. Which drug, and when, for patients with BRAFmutant melanoma? Lancet Oncol, 2013,14:e60-e69.
4. Chen W, Zheng R, Zhang S, et al. The incidences and mortalities of major cancers in China, 2010. Chin J Cancer, 2014,33:402-405.
5. Kubica AW, Brewer JD. Melanoma in immunosuppressed patients. Mayo Clin Proc, 2012,87:991-1003.
6. Romo-Tena J, Gomez-Martin D, Alcocer-Varela J. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev, 2013,12:1171-1176.
7. Feng XL, Smylie M, Cheng T, et al. The impact of clinical response to anti-CTLA4 treatment on overall survival (OS) in metastatic melanoma (MM). J Clin Oncol (meeting abstracts), 2014,32:15-suppl 9080. Available at: http://meeting.ascopubs.org/cgi/content/ abstract/32/15_suppl/9080?sid=55766fbf-0d39-4eda-8665-85ff1fac2f85.
8. Shahabi V, Whitney G, Hamid O, et al. Assessment of association between braf-v600e mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol Immunother, 2012,61:733-737.
9. Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer, 2013,119:1675-1682.
10. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010,363:711-723.
11. Ascierto PA. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies. Tumori, 2013,99:302e-305e.
12. Marlier J, Cocquyt V, Brochez L, et al. Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports. Endocrine, 2014 Feb 21. [Epub ahead of print].
13. Torino F, Barnabei A, Paragliola RM, et al. Endocrine sideeffects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol, 2013,169:R153-164.
14. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med, 2011,364:2517-2526.
15. Jamal R, Belanger K, Friedmann JE, et al. A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM). J Clin Oncol (meeting abstracts), 2014,32:15_suppl 9066. Available at: http://meeting.ascopubs.org/cgi/content/abstract/32/15_ suppl/9066?sid=d88fee02-9cc2-48d6-b947-1a12933b8ea1.
16. Ackerman A, Klein O, McDermott DF, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer, 2014,120:1695-1701.
17. Chasset F, Pagès C, Biard L, et al. Single-center experience in French Temporary Authorization for Use (TAU) metastatic melanoma program with ipilimumab. J Clin Oncol (meeting abstracts), 2014,32:15_supple 20034. Available at: http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/ e20034?sid=a4a9adcb-36ee-43db-8df6-66972e5e1156.
18. Eggermont AM, Grob JJ, Dummer R, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. J Clin Oncol (meeting abstracts), 2014,32:18_suppl LBA9008. Available at: http://meeting.ascopubs.org/cgi/content/ abstract/32/18_suppl/LBA9008?sid=e65ba47c-6221-43c7-ae65-f680998d22bd.
19. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol, 2005,23:8968-8977.
20. Kirkwood JM, Lorigan P, Hersey P, et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res, 2010,16:1042-1048.
21. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol, 2013,31:616-622.
22. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol, 2008,26:677-704.
23. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med, 2013,369:134-144.
24. Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res, 2013,19:462-468.
25. Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or-naive melanoma. J Clin Oncol, 2013,31:4311-4318.
26. Hodi FS, Sznol M, Kluger HM, et al. Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. J Clin Oncol (meeting abstracts), 2014,32:15_ suppl 9002. Available at: http://meeting.ascopubs.org/cgi/content/ abstract/32/15_suppl/9002?sid=5fe47f07-074b-4963-b8c8-2bdfb7c44af7.
27. Weber JS, Kudchadkar RR, Gibney GT, et al. Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, ipilimumab (IPI). J Clin Oncol (meeting abstracts), 2014,32:15_suppl 3009. Avalialbe at: http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3009?sid=79ccfaca-ae72-4c86-a796-a9d47d32505a.
28. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-deathreceptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, 2014 Jul 14. doi: 10.1016/S0140-6736(14) 60958-2. [Epub ahead of print].
29. Ribas A, Hodi FS, Kefford R, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol (meeting abstracts), 2014,32:18_ suppl LBA9000. Available at: http://meeting.ascopubs.org/cgi/content/abstract/32/18_suppl/LBA9000?sid=53482d36-be89-408e-a182-31dc8af59124.
30. Hamid O, Robert C, Ribas A, et al. Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and ipi-naive (IPI-N) melanoma (MEL). J Clin Oncol (meeting abstracts), 2014,32:15_suppl 3000. Available at: http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3000?sid=a0af207c-9694-4432-96ee-405a3816376e.
31. Lee SW, Croft M. 4-1BB as a therapeutic target for human disease. Adv Exp Med Biol, 2009,647:120-129.
32. Liu SYLY. Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. Clin Pharmacol, 2013,5:47-53.
33. Castro MG, Baker GJM, Lowenstein PR. Blocking immunosuppressive checkpoints for glioma therapy: the more the merrier! Clin Cancer Res, 2014 May 30. [Epub ahead of print].
34. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med, 2013,369:122-133.
35. Sznol M, M. Kluger HM, Margaret K, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol (meeting abstracts), 2014,32:18_suppl LBA9003. Available at: http://meeting.ascopubs.org/cgi/content/abstract/32/18_suppl/LBA9003?sid=96f27b34-e1a8-4ea7-8851-21476aa16fcf.
36. de Rosa F, Ridolfi L, Ridolfi R, et al. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alpha in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study. J Transl Med, 2014, 12:209.
37. Vansteenkiste J, Zielinski M, Linder A, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol, 2013,31:2396-2403.
38. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol, 2012,30:658-670.
39. Linette GP, Carreno BM. Dendritic cell-based vaccines: shining the spotlight on signal 3. Oncoimmunology, 2013,2:e26512.
40. Salazar-Onfray F, Pereda C, Reyes D, et al. Tap cells, the chilean dendritic cell vaccine against melanoma and prostate cancer. Biol Res, 2013,46:431-440.
41. Baldueva IA, Novik AV, Moiseenko VM, et al. Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients. Vopr Onkol, 2012,58:212-221.
42. [in Russian]
43. Dannull J, Haley NR, Archer G, et al. Melanoma immunotherapy using mature dcs expressing the constitutive proteasome. J Clin Invest, 2013,123:3135-3145.
44. Ellebaek E, Engell-Noerregaard L, Iversen TZ, et al. Metastatic melanoma patients treated with dendritic cell vaccination, interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol Immunother, 2012,61:1791-1804.
45. Oshita C, Takikawa M, Kume A, et al. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep, 2012,28:1131-1138.
46. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer, 1999,80:219-230.
47. Meek DW, Marcar L. MAGE-A antigens as targets in tumour therapy. Cancer Lett, 2012,324:126-132.
48. Kruit WH, van Ojik HH, Brichard VG, et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer, 2005,117:596-604.
49. Kruit WH, Suciu S, Dreno B, et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol, 2013,31:2413-2420.
50. Ben H. GSK cancer vaccine disappoints in melanoma trial. Reuters, 2013 Sept 5. Aviable at: http://www.reuters.com/article/2013/09/05/ us-glaxosmithkline-melanoma-idusbre98406w20130905.
51. Liu BL, Han ZQ, Branston RH, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther, 2003,10:292-303.
52. Senzer NNKH, Amatruda T, Nemunaitis M, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor encoding, second-generation oncolytic herpes virus in patients with unresectable metastatic melanoma. J Clin Oncol, 2009,27:5763-5771.
53. Kaufman HL, Andtbacka RHI, Collichio FA, et al. Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol (meeting abstracts), 2014,32:15_suppl 9008a. Available at: http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9008a?sid=8e6e0101-4d63-4680-a3f3-b910f424c05c.
54. Update-1 Amgen melanoma drug fails to improve overall survival rates. Reuters, 2014 Apr 4. Aviable at: http://www.reuters.com/ article/2014/04/04/amgen-melanoma-idCNL4N0MW3AL20140404.
55. Puzanov I, Milhem MM, Andtbacka RHI, et al. Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (IPI) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol (meeting abstracts), 2014,32:15_suppl 9029. Available at: http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9029?sid=6eb4029c-0ebb-49ef-b2bd-a1d959f2d484.
56. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumorinfiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med, 1988,319:1676-1680.
57. Smith KA. Interleukin-2: inception, impact, and implications. Science, 1988,240:1169-1176.
58. Gillessen S, Gnad-Vogt US, Gallerani E, et al. A phase I doseescalation study of the immunocytokine EMD 521873 (selectikine) in patients with advanced solid tumours. Eur J Cancer, 2013,49:35-44.
59. Laurent J, Touvrey C, Gillessen S, et al. T-cell activation by treatment of cancer patients with EMD521873 (Selectikine), an IL-2/ anti-DNA fusion protein. J Transl Med, 2013,11:5.
60. Kaufman HL, Mehnert JM, Cuillerot J, et al. Targeted modified IL-2 (NHS-IL2, MSB0010445) combined with stereotactic body radiation in advanced melanoma patients after progression on ipilimumab: assessment of safety, clinical, and biologic activity in a phase 2a study. J Clin Oncol (meeting abstracts), 2014,32:15_suppl TPS9107. Available at: http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS9107?sid=c346407f-74a5-4150-9274-ebf40a25dd45.
61. Elias EG, Sharma BK. Tumor response and patient survival after intralesional therapy with low-dose GM-CSF and IL-2 in metastatic and primary cutaneous melanoma: an exploratory study. J Clin Oncol (meeting abstracts), 2014,32:15_supple 20002. Available at: http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e20002?sid=bec1137b-9959-407b-a9ec-b0e4ca0951e5.
62. Dillman RO, Barth NM, VanderMolen LA, et al. Should highdose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm, 2012,27:337-343.
63. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol, 2005,23:133-141.
64. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol, 2009,27:6199-6206.
65. Daud A, Algazi AP, Ashworth MT, et al. Systemic antitumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma. J Clin Oncol (meeting abstracts), 2014,32:15_suppl 9025. Available at: http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9025?sid=784dd2db-982d-4632-9123-67e81b7a2e55.
66. Ismail A, Yusuf N. Type I interferons: key players in normal skin and select cutaneous malignancies. Dermatol Res Pract, 2014,2014:847545.
67. Suciu S, Ives N, Eggermont AM, et al. Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): an individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts). J Clin Oncol (meeting abstracts), 2014,32:15_suppl 9067. Available at: http://meeting.ascopubs.org/cgi/content/abstract/32/15_ suppl/9067?sid=07e3681f-40a6-4e23-94c7-cf78f2135b96.
68. Simons DL, Lee G, Kirkwood JM, et al. Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med, 2011,9:52.
69. Herndon TM, Demko SG, Jiang X, et al. U.S. Food and Drug Administration Approval: peginterferon-alfa-2b for the adjuvant treatment of patients with melanoma. Oncologist, 2012,17:1323-1328.
70. Eggermont AM, Suciu S, Testori A, et al. Long-term results of the randomized phase III trial EORTC18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol, 2012,30:3810-3818.
71. Go RS, Lee SJ, Shin D, et al. ECOG phase II trial of graded-dose peginterferon alpha-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602). Clin Cancer Res, 2013,19:6597-6604.
72. Eigentler TK, Gutzmer R, Hauschild A, et al. Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa (T3a): IIIb (AJCC 2002)—DeCOG-trial. J Clin Oncol (meeting abstracts), 2014,32:15_suppl 9071. Available at: http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9071?sid=c3ac38d9-0279-4d16-98f8-66fc1f410135.
73. Kudchadkar RR, Gibney GT, Dorman D, et al. A phase IB study of ipilimumab with peginterferon alfa-2b for patients with unresectable stages IIIB/C/IV melanoma. J Clin Oncol (meeting abstracts), 2014,32:15_suppl 9098. Available at: http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9098?sid=386f4af7-be4d-4279-930c-ec01070b1e78.
74. Stones CJ, Kim JE, Joseph WR, et al. Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Front Genet, 2013,4:66.
75. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med, 2012,367:107-114.
76. Trunzer K, Pavlick AC, Schuchter L, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol, 2013,31:1767-1774.
77. Beck D, Niessner H, Smalley KS, et al. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal, 2013,6:ra7.
78. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAFmutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 2012,380:358-365.
79. Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/ MEK2 inhibitor trametinib in patients with metastatic braf-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol, 2013,31:482-489.
80. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med, 2012,367:1694-1703.
81. Acquaviva J, Smith DL, Jimenez JP, et al. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Mol Cancer Ther, 2014,13:353-363.
82. Di Cresce C, Koropatnick J. Antisense treatment in human prostate cancer and melanoma. Curr Cancer Drug Targets, 2010,10:555-565.
83. Ott PA, Chang J, Madden K, et al. Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. Cancer Chemother Pharmacol, 2013,71:183-191.
84. Aixinjueluo W, Furukawa K, Zhang Q, et al. Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. J Biol Chem, 2005,280:29828-29836.
85. Eissler N, Ruf P, Mysliwietz J, et al. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. Cancer Res, 2012,72:3958-3966.